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Abstract 
Background: MS is a highly heterogeneous disease, both in its course and in its 
response to treatments. Effective biomarkers may help predict disability progression 
and monitor patients’ treatment responses. 
Objective: To focus on how biomarkers may contribute to treatment individualisation 
in MS patients.  
Methods: This review reflects the content of the presentations, polling results and 
discussions on the clinical perspective of MS during the first and second Pan-
European MS Multi-stakeholder Colloquia in Brussels in May 2014 and May 2015. 
Results: In clinical practice, MRI measures play a significant role in the diagnosis and 
follow-up of patients with MS. Together with clinical markers, the rate of MRI-visible 
lesion accrual once a person with MS has started treatment may also help to predict 
subsequent treatment responsiveness. In addition, several molecular (immunological, 
genetic) biomarkers have been established that may also play a role in predictive 
models of MS relapses and progression. To reach personalised treatment decisions, 
estimates of disability progression and likely treatment response should be carefully 
considered alongside the risk of serious adverse events, together with the patient’s 
treatment expectations. 
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Conclusion: Although biomarkers may be very useful for individualised decision 
making in MS, many are still research tools and need to be validated before 
implementation in clinical practice.   
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Introduction 
MS is classically regarded as an idiopathic inflammatory demyelinating and 
neurodegenerative disease of the CNS. Most prevalence estimates of MS in western 
countries vary between 25 and 200 per 100,000, with incidences peaking around 30 
years of age.1  The disease is nowadays thrice as common in women than in men and 
is the leading cause of non-traumatic neurological disability in young adults in western 
countries.2 
Because part of the disease process in MS is clinically silent over a long period of 
time, for example the number of new brain lesions seen on MRI is substantially 
greater than the number of relapses occurring over the same period,3 surrogate markers 
for disease activity and progression have been identified and have served as outcome 
measures in clinical trials. At present, the most important para-clinical measures 
predicting a patient’s prognosis are changes in the CNS detected using MRI. In recent 
years, several prognostic molecular biomarkers have been evaluated as well. In 
addition, some biomarkers may assist in predicting a patient’s treatment response. 
These markers may be useful to identify poor responders early on and to switch them 
to an alternative, more effective, therapy before substantial neurological damage has 
occurred. Alternatively, biomarkers may be used to predict a patient’s risk of 
developing serious adverse events (SAEs) on treatment with a particular drug.4,5 It 
should be noted that biomarkers that have proven valuable on a group level in clinical 
trials may not be suitable for the evaluation of individuals. In addition, the interval 
between measurements can (in part) have an impact on the sensitivity to clinically 
relevant changes.6 
The current and future potential of biomarkers for predicting the disease course, 
treatment response and tolerability was discussed during the first and second Pan-
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European MS Multi-stakeholder Colloquium, which took place on 23-24 May 20147 
and 15-16 May 20158 in Brussels. The goal of these colloquia was to enhance the 
communication and collaboration between the different stakeholders involved in MS 
care, including patients and their caregivers, healthcare professionals, researchers, 
regulators and payers. The programmes developed by the chair and scientific committee 
aimed at prioritising actions needed to improve the quality of and access to care and 
treatment. At the first colloquium, after introductory presentations on various subjects 
by the different stakeholders, the audience was asked to rank priorities from a list of 
potential action points. The outcome of this polling was used to stimulate further 
discussions among the speakers, a group of experts in the field and the audience during 
the first and second colloquium. 
This review summarises the content of the presentations, polling results and discussions 
related to the use of risk factors and clinical, MRI and other biomarkers in MS and their 
current and future utility for the individualisation of treatment. 
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Predicting disease progression 
Clinical markers of disease progression 
Relapses 
Several studies have suggested an association between a higher relapse rate in the first 
2-5 years after disease onset and a shorter first inter-relapse interval on the one hand 
and a more rapid disability progression on the other hand (Figure 1).9-13 However, this 
predictive effect seems to disappear once the progressive course starts (e.g. when an 
Expanded Disability Status Scale (EDSS) score of 3-4 is reached) (Figure 2). Mean 
times from disease onset, progressive phase onset and an EDSS 3 to reaching EDSS 6, 
8, and 10 are strikingly similar for patients with different relapse numbers in the 
relapsing-remitting (RR) phase.10 Also in patients with progressive onset MS, 
superimposed relapses do not appear to affect long-term outcomes.14 However,  an 
important point that we should consider in evaluating these results is that the main 
measure of disability (EDSS) used in these studies and in daily clinical practice has 
significant limitations: EDSS in the 4–7 range is insensitive to change in any 
functional system other than ambulation. Relapses affecting upper limb or brain stem 
function or cognition, more prevalent in later phases of the disease, might not affect 
the EDSS score. These limitations might explain the limited ability of EDSS to detect 
a delayed impact of relapses on disability progression.15  
 
MRI markers of disease progression  
MRI lesions detected using conventional techniques 
Conventional MRI techniques, such as spin-echo and fluid-attenuated inversion 
recovery (FLAIR) T2-weighted and unenhanced and contrast-enhanced T1-weighted 
sequences mainly detect focal lesions or plaques in the brain and spinal cord of MS 
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patients. Classical MRI measures in MS, which can be evaluated using these 
techniques are the number and volume of gadolinium-enhancing (GdE) lesions, 
hyperintense lesions on T2-weighted scans and hypointense ‘black holes’ on T1-
weighted scans. The number of GdE lesions has been found to be associated with the 
risk for future relapse and relapse rate.16 However, subclinical activity detected using 
conventional MRI may occur at a 5 to 10 times higher rate than clinical observations 
would suggest.17 Anomalies in the CNS suggestive of MS may also be identified by 
MRI before there is clinical evidence of the disease. This is referred to as 
‘radiologically isolated syndrome’ (RIS). In a retrospective study including 451 of 
subjects with RIS, about one-third of these subjects had a first clinical event within 5 
years of the first brain MRI study (at a mean age of 37.2 years).18 Lesions within the 
cervical or thoracic spinal cord were identified as significant predictors for the 
development of a first clinical event (hazard ratio [HR] 3.08), together with younger 
age (HR 0.98, i.e. an estimated risk of developing an event decreasing by 2% for every 
additional year of age) and male sex (HR 1.93) (Figure 1). 
The presence of GdE lesions and T2 hyperintense lesions is an important diagnostic 
criterion in MS, because of the established association between the number and 
volume of these lesions and conversion from clinically isolated syndrome (CIS) to 
clinically definite MS (CDMS) (Figure 1).19-22 Despite their association with relapse 
rate, relatively weak correlations have been reported between conventional lesion 
metrics and disability progression, as measured using the EDSS.21,23,24 In patients with 
relapsing-remitting MS (RRMS), early progression of T2 lesion load appears to 
predict progression to SPMS to some extent, but there appears to be little association 
between the burden of T2 lesions and future disability for EDSS values above 4.5 
(Figure 2).24,25 Chronic T1 hypointense lesions, detected on spin-echo sequences, have 
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shown a better correlation with EDSS than GdE and T2 lesions,26 and these lesions are 
believed to reflect severe and irreversible axonal damage.27 Although potentially 
clinically relevant, T1-hypointese lesion assessment is still subjective and highly 
dependent on the type of T1-weighted sequence and field strength.28 When 
considering the predictive role of MRI lesions it should be noted that the number of 
lesions accumulated over time may be a better predictor of future disability than the 
number of active (GdE) lesions at a single time point.29 Moreover the predictive value 
of active lesions may be higher in the early RR phase than later in the disease 
evolution.25,30 
 
Brain atrophy 
Pathophysiological research over the past decades has shown that conventional MRI 
measures do not tell the full history of MS. Whereas focal inflammation and axonal 
demyelination in the WM seem to be mainly associated with relapses, axonal/neuronal 
loss is currently believed to be the main driver of irreversible disability progression. 
These insights have triggered interest in measuring tissue volume loss (atrophy) in the 
CNS as a marker of neurodegeneration. Several MRI techniques to measure brain 
volume loss (and in case of sustained volume loss as per definition: atrophy) such as 
segmentation-based or registration-based methods have been introduced in the past. 
Segmentation-based methods measure global or regional brain volume (e.g. brain 
parenchymal fraction, white matter fraction, grey matter fraction, normalized brain 
volume) at a single time point. Registration-based methods measure brain volume at 
two time points, in order to calculate the percentage brain volume change (PBVC), 
and are most suitable for evaluating global brain volume changes,31 but are not usually 
designed to analyse regional volume changes over time.32,33 
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Studies have shown that brain atrophy affects the entire brain in MS, including white 
matter (WM) and grey matter (GM), and starts very early in the disease course.34,35 
Although some studies suggested that brain atrophy escalates with increasing disease 
stage, this was not confirmed in a large MAGNIMS (Magnetic Resonance Imaging in 
MS) study when data were corrected for baseline normalised brain volume.36,37 An 
association between increasing early brain tissue volume loss and increasing long-term 
disability progression has been shown in several studies (Figure 2).38-41 GM volume 
was found to be a stronger predictor of clinical disability than WM volume.39 
Measuring brain atrophy is challenging because the change in volume over time is 
relatively small. In MS patients, brain atrophy occurs at a rate of 0.5-1.3% per year, 
compared with 0.1-0.3% per year reported for healthy subjects.34,42 Although the 
estimation of brain atrophy seems to be an important prognostic marker, its 
implementation in the clinical workflow is limited by several factors. 
As brain atrophy is not necessarily linear, progression in individuals is hard to predict. 
Also, no common agreement on a single measurement technique to be used in clinical 
research or clinical practice currently exists. Differences between techniques limit 
direct comparison between results. Furthermore, several other confounding factors 
must be considered when evaluating disease progression based on brain volume 
loss/atrophy, including image acquisition and quality (e.g. imperfect skull extraction 
and outlining, imprecise registration, issues due to patient movement), the effect 
lesions can have on tissue segmentation (for example due to classification of T1 
hypointense lesions as GM), pseudo-atrophy (reduction in inflammation due to 
disease-modifying treatment), change in brain water content due to hydration status or 
steroid use or even diurnal fluctuations, and other factors such as cardiovascular 
disease, smoking, high alcohol consumption, and genetic factors.43,44 Although brain 
Mult Scler  SUPPLEMENT MS Multi-stakeholder Colloquia: The Clinical Perspective 
final, 11/01/2016  10 
atrophy measures are very valuable for group analysis, both biological and technical 
variability need to be improved to make them suitable for individual analysis. 
 
Advanced MRI measures 
The introduction of new advanced imaging techniques, including sensitive techniques 
to quantify diffuse damage or metabolic or functional changes in tissue appearing 
normal on conventional MRI scans, has considerably improved the detection of 
pathological changes in MS.17  
A promising new sequence for diagnostic set-up and follow-up is double-inversion 
recovery (DIR). DIR has considerably improved the ability to detect cortical lesions in 
patients with MS. Studies have shown accumulation of cortical lesions over time and 
correlations with clinical and cognitive dysfunction.42 The presence of at least one 
cortical lesion has been found to be associated with an increased risk of conversion 
from CIS to CDMS.45 Cortical lesion volume and number have also been found to 
independently predict future disability accumulation in RRMS, SPMS and PPMS 
patients (Figure 2).46,47 However, about 80% of GM lesions still remain undetected 
with this technique.48 DIR very rarely detects subpial cortical lesions,48 which is the 
most abundant and specific cortical lesion type seen in histopathological work. There 
is no common sequence recommendation for cortical lesion detection, and DIR inter-
rater reliability of cortical lesion scoring using consensus guidelines was found to be 
low, with a complete agreement on only ~20% of lesions between readers.49 
Magnetisation transfer imaging (MTI) measures correlate with demyelination, 
remyelination and axonal loss.50 MTI variables in GM and normal-appearing WM 
have been found to independently predict future disability (EDSS) progression in the 
long term (3-8 years) in patients with RRMS, secondary progressive MS (SPMS) and 
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primary progressive MS (PPMS) (Figure 2).51-53 However, MTI is time-consuming 
and its use in individuals is limited by the variability across sites (as the results depend 
on the method used) and the lack of normative values, which is a problem common to 
many current quantitative MRI techniques. 
Proton magnetic resonance (MR) spectroscopy can provide information about 
metabolic changes in normal-appearing brain tissue and focal lesions. Reductions of 
N-acetyl-aspartate (NAA) levels (suggestive of neuroaxonal damage) are partly 
reversible and an association between greater increases in NAA levels after spinal 
relapse and greater recovery has recently been described.54 However, MR 
spectroscopy is time consuming and has a greater biological variability than other 
structural methods, and measures are method- and scanner-specific. Therefore, this 
technique is currently not considered suitable for use in multi-centre studies.  
 
Optical coherence tomography (OCT) 
MS patients typically show thinning of particularly the innermost layers of the retina, 
even without a history of optic neuritis (ON).55 Some studies have shown an inverse 
relationship between inner nuclear layer thickness and EDSS (progression).56,57 
Recently, a strong correlation between ganglion cell/inner plexiform atrophy and 
whole-brain, especially GM, atrophy, was established, particularly in patients with 
progressive MS, suggesting that it mirrors underlying disease progression.58 Despite 
promising results, more large longitudinal studies are needed to evaluate the 
prognostic value of OCT in MS. A limitation of OCT is that measurements are 
affected by a history of ON, lesions elsewhere in the visual pathway and non-MS 
ocular conditions.55 In addition, magnitudes of annual thinning of retinal layers are 
smaller than the variability between measurements.55  
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Evoked potentials (EPs) 
A number of studies have suggested that multimodal EPs (nerve latencies) may be 
valuable for monitoring and predicting disability in MS patients.59 Although their 
diagnostic value is considered poor compared with MRI,59 several studies have shown 
correlations between EP measures and (future) disability.59-61 However, its use in 
clinical practice requires standardisation within and between laboratories. 
 
Molecular  biomarkers  
Apart from MRI, several molecular biomarkers have been identified for diagnosing 
MS and for monitoring and predicting disability progression.  
The presence of immunoglobulin (Ig) G oligoclonal bands (OCB) and/or an elevated 
IgG index in the cerebrospinal fluid (CSF) support the diagnosis of MS in patients 
suspected to have demyelinating disease, but they do not contribute to proof of MS in 
the 2010 McDonald criteria. The best validated molecular biomarkers that predict 
conversion to CDMS in patients with CIS are the presence of IgG OCB62,63 and the 
IgG index62 in the CSF. Recently, serum auto-antibodies directed against the 
potassium channel KIR4.1 have been suggested as a candidate biomarker for the 
diagnosis of MS.64 They are already detectable in the early stages of MS and have an 
excellent specificity but low sensitivity. However, a recent validation study could not 
replicate this finding in independent cohorts.65  
Another CSF biomarker with strong evidence is Chitinase 3-like 1 (CHI3L1), which is 
expressed on monocytes and microglial cells and has been linked to astrocyte 
activation. CHI3L1 has not only been shown to predict conversion to CDMS66,67 but 
also to predict more rapid disability progression.66,67 Recently, the level of vitamin D 
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in blood has been suggested as a candidate biomarker for conversion to CDMS62,68 and 
more rapid disability progression.68,69 In a study including patients with CIS, who 
were mainly treated with interferon (IFN) β-1b, low serum levels of 25-
hydroxyvitamin D (a marker of vitamin D status) predicted long-term clinical and 
MRI activity.68  Furthermore, lower serum 25-hydroxyvitamin D levels were also 
associated with lower MRI activity in RRMS patients treated with IFNβ-1b in the 
prospective BEYOND study.69 However, these data should be further confirmed by 
other investigators before vitamin D can be used as a valid biomarker. In the future, 
biomarkers predicting conversion to CDMS may become useful in the decision which 
patients with CIS could benefit from early treatment initiation.  
As mentioned above a number of molecular biomarkers for predicting future disease 
activity have been suggested as well, including CHI3L1 and vitamin D levels. In 
addition, the neurofilament (NF) levels in the CSF and blood have been suggested as 
biomarker for predicting disability progression. NFs are major axonal cytoskeleton 
proteins, consisting of a light chain (NFL), an intermediate chain (NFM) and a heavy 
chain (NFH). NFL and NFH concentrations in CSF are used in clinical practice as 
surrogate endpoints of neuroaxonal damage. Indeed, NFL levels seem to correlate with 
acute axonal damage,70 while NFH levels may reflect chronic axonal damage and may 
be more strongly associated with disability progression.71,72 Furthermore, serum NFL 
levels appear to correlate with MRI activity and disability scores and may present an 
easily accessible biomarker predicting disability progression.73 
Although these molecular biomarkers may gain importance in the future, their 
integration into clinical practice requires further evaluation. Longitudinal studies in 
large cohorts of patients are needed to better assess the natural history of MS in 
relation to baseline levels of these biomarkers. 
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Predicting treatment response and tolerability 
Initiation of the right drug at the right time is a crucial goal in MS in order to minimise 
further inflammation, neurodegeneration and resulting irreversible disability 
progression.74 The majority of patients with RRMS will start with a first-line disease-
modifying drug (DMD) with a moderate efficacy but a good safety profile (e.g. IFNβ, 
glatiramer acetate (GA), teriflunomide, dimethyl fumarate (DMF)).75 In those who fail 
to respond to these agents, this is followed by second-, third-, fourth- or even fifth-line 
treatments (Figure 4). For each treatment step, drug efficacy may increase along with 
the associated risk of serious adverse events (SAEs). However, for patients with a high 
disease activity, starting therapy with highly effective but aggressive therapies such as 
natalizumab (NTZ) or alemtuzumab (ATZ) (also referred to as induction therapy) may 
be appropriate to rapidly reduce disease activity. Once disease control has been 
achieved, therapy can be scaled back to better tolerated −but potentially less 
efficacious− drugs for long-term maintenance.75 Current experience with induction 
therapy is limited, particularly its immunogenic effect in the long term, and not tested 
against escalation strategies in randomised controlled trials. 
As not all patients will sufficiently respond to first-line treatment, and conversely not 
all patients will develop SAEs upon treatment with highly aggressive drugs, it would 
be very useful to be able to predict a patient’s likely treatment response and risk of 
SAEs. In this way, poor responders can be switched to an alternative therapy early on, 
before substantial neurological damage has occurred, and patients can be spared from 
potential SAEs associated with a particular drug, such as progressive multifocal 
leukoencephalopathy (PML) upon treatment with NTZ or autoimmune disorders upon 
treatment with ATZ.4,5 Therefore, current research is focusing on the identification of 
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clinical, imaging, immunological and genetic biomarkers that may help individualise 
treatment. 
 
Response to first-line treatments 
Response to IFNβ and GA 
Regarding the injectable first-line DMDs IFNβ and GA, direct comparative studies 
have not shown superiority of one drug over another in terms of efficacy (BEYOND76, 
REGARD77). Moreover, these trials do not give any indication on the most appropriate 
first-line treatment choice at the patient-specific level. Additionally, surrogate markers 
are needed to predict which patients will respond to first-line DMDs. Several studies 
have shown that, in patients with RRMS, high disease activity, i.e. high frequency of 
relapse, high rate of disability progression and/or high number of MRI lesions at 
baseline or in the first year of treatment, may predict (mid- and long-term) failure to 
IFNβ and GA.5,78-83  
Next to these clinical and MRI measures, the titre of neutralising antibodies (NAbs) 
against IFNβ has been established as a clinically useful predictor of poor treatment 
response.84 Indeed, NAbs reduce the therapeutic effect of IFNβ on relapse rate and 
MRI lesion activity.84,85 Therefore, for patients with sustained high-titre NAbs 
consideration should be given to DMDs other than IFNβ84. In addition, other 
immunological biomarkers have been suggested to predict response to IFNβ in 
patients with RRMS, including several chemokines and cytokines.4,72 However, for 
most of them, e.g. serum interleukin-17F (IL-17F), the predictive value is still highly 
debated.86,87 Moreover, for those markers that have already been validated, usefulness 
in clinical practice still needs to be demonstrated.72  
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Furthermore, many pharmacogenomics studies have tried to identify genetic variants 
that may predict response to IFNβ or GA. So far, two genome-wide association studies 
have suggested a role for GPC5, glutamate receptors and ADAR in response to IFNβ.88 
Very few studies have evaluated the pharmacogenomics of response to GA.88-90 To 
bring pharmacogenomics from academic research to clinical practice, a joint effort 
between academy and industry is necessary.91 A large-scale pharmacogenomics study 
in GA-treated RRMS patients, including consenting patients from the FORTE 
(N=604) and the GALA studies (N=1,158), is currently ongoing.92 An 11-single 
nucleotide polymorphisms (SNP) signature for GA response was identified in the 
GALA study and validated in the FORTE study. This multi-SNP signature may be 
able to predict which GA-naïve RRMS patients will be high responders, exhibiting 
annualised relapse rate (ARR) reductions significantly higher than the average 
response (≈33%) reported in clinical trials.92 The predictive value of this multi-SNP 
signature is being validated in an independent cohort. 
 
Response to oral first-line DMDs 
Due to the development of several oral DMDs, the therapeutic landscape of MS has 
considerably changed over the last decade; first-line treatment choice has even become 
more complex. So far, there are no efficacy data showing superiority of the new oral 
drugs (e.g. teriflunomide, DMF) over IFNβ or GA. Indeed, the CONFIRM study was 
designed to show superiority or non-inferiority of DMF (twice or three times daily) vs 
placebo, and not vs GA, which was only added as a reference comparator.93 Similarly, 
the TENERE study did not show a statistical difference in time to treatment failure 
between teriflunomide (7 or 14 mg) and IFNβ-1a.94 Thus, again, these data do not 
facilitate the personalised treatment decision between oral and injectable first-line 
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DMDs and biomarkers are needed to predict the patient’s treatment response to DMF 
or teriflunomide. However, to our knowledge, no such biomarkers have been 
described yet.72,95 It remains to be investigated whether new imaging techniques such 
as MTI and diffusion tensor MRI, OCT or positron emission tomography may be 
useful for this purpose.95  
 
Response to second-line treatments 
A promising biomarker which objectively reflects response to second-line treatments 
is the level of NFs in the CSF.72,95 NFL concentration in CSF can serve as surrogate 
endpoint of neuroaxonal damage71,72 and thus as surrogate endpoint for treatment 
efficacy. Although NFL levels in CSF were shown to be reduced upon treatment with 
NTZ,96,97 fingolimod,98 mitoxantrone or rituximab99, the predictive value on individual 
patients is very modest. A potential disadvantage of this biomarker is the need for a 
lumbar puncture to collect CSF. However, a recent study has shown reduced serum 
levels of NFL antibodies in NTZ-treated RRMS patients, suggesting that they may 
also serve as a biomarker of treatment efficacy as well.100 However, their usefulness 
still needs to be confirmed in clinical practice.  
Biomarkers that may predict response to second-line drugs, such as SNPs in the ABC 
transporter genes for mitoxantrone,101 are still in the exploratory or validation phase.72  
 
 
Tolerability 
An established immunological biomarker to predict a patient’s risk of SAEs is the 
presence of anti-John Cunningham virus (JCV) antibodies (anti-JCV-Abs) in 
serum.4,72 In patients treated with NTZ, positive anti-JCV-Ab status, longer duration of 
treatment with NTZ and prior immunosuppressive treatment were shown to be 
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associated with an increased risk of PML.102 Based on these 3 parameters, a risk 
stratification algorithm was developed to counsel patients treated with or considering 
treatment with NTZ on their risk of PML. Anti-JCV-Ab positive patients with no prior 
use of immunosuppressants may even be further stratified according to their anti-JCV-
Ab index, which is a corollary to anti-JCV-Ab titre. Patients whose anti-JCV-Ab index 
is more than 1.5 and whose treatment duration is longer than 24 months, have been 
shown to have a substantially greater risk of PML.103 Thus they should be encouraged 
to switch to an alternative drug or undergo strict monitoring  (including frequent MRI 
scanning) to detect PML if NTZ is not discontinued.104 
Similarly, patients developing secondary autoimmunity (autoimmune thyroid disease, 
idiopathic thrombocytopenic purpura) following treatment with ATZ were shown to 
have two-fold greater pre-treatment serum levels of IL-21. The original IL-21ELISA 
kit, containing antibodies from ascites, has been recently withdrawn in order to switch 
to the more ethical cell culture-based antibody ELISA kits.105,106 However, a recent 
study has shown that the currently available IL-21 kits have little or no predictive 
value for the risk to develop secondary autoimmunity on ATZ treatment.106 
Finally, increased risk of developing secondary acute promyelocytic leukaemia 
(sAPL) after treatment with mitoxantrone was suggested to be linked to genetic 
variants in DNA repair and drug-metabolising enzymes (BRCA2, XRCC5, CYP3A4), 
resulting in impaired detoxification of chemotherapy or inefficient repair of drug-
induced genetic damage.107,108 More research efforts are needed to identify other 
biomarkers that may predict drug tolerability at the patient-specific level. 
 
Implementation of biomarkers in clinical routine 
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MRI measures remain the most important biomarkers for diagnosis and routine 
follow-up of patients with MS in clinical practice. Brain WM and GM lesion volumes 
and brain atrophy measures all correlate with disability scores, and can be undertaken 
using images that can be acquired with all conventional clinical MRI scanners. 
Beyond the role of WM lesions in the diagnosis of MS, it has yet to be determined 
how MRI and molecular biomarkers can be usefully integrated into patient-specific 
measures for routine use in clinical practice. 
An important issue that hampers implementation of MRI in multifactorial decision 
models and their integration into the routine clinical workflow is the lack of 
standardised MRI protocols for monitoring disease evolution, particularly for patients 
receiving DMDs. A standardised basic MRI acquisition protocol should be simple and 
feasible, robust, fast (around 30 min), scanner vendor-independent, field strength-
independent, and supported by national and international scientific societies, payers, 
and pharmaceutical companies. A standardised MRI acquisition protocol for the 
diagnosis and follow-up of MS patients has been recently developed by MAGNIMS 
network (Table 1).109 European and national MS as well as neurological and 
(neuro)radiological societies can play an important role in the implementation of this 
protocol by supporting its use in clinical practice. As differences in MRI outcomes 
between centres may be in the same range or even exceed yearly changes due to 
disease progression or differences between placebo and treatment groups observed in 
clinical trials, ideally the same MRI machine and protocol should be used in the same 
patient for a many years as is feasible. 
Integration of MRI into routine clinical practice also requires further automation of 
measurements and evaluation.110 There is need for fully automated pipelines to 
perform high quality cross-sectional / longitudinal volumetric analysis, with automated 
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detection and filling of lesions (to lessen their confounding effect on atrophy 
measures). These tools should be integrated in all major MR vendors’ post-processing 
software and allow transfer of information into Picture Archiving and Communication 
Systems (PACS). Although outsourcing of specialised MRI analysis to dedicated 
companies may be a good solution for the short term, the pipelines should eventually 
become integrated into clinical routine allowing fast interpretation of images by 
(neuro)radiologists. 
Not only the MRI protocols, but also the way MRI results are reported by radiologists 
should be standardised, and combine conventional (written) and structured reports. 
Dedicated teaching courses for radiologists on MRI standards in MS and interpretation 
of images could be conducted on a regular basis in order to deepen skills and 
knowledge of MRI in MS. This will facilitate and improve the communication 
between radiologists and clinicians and support analysis for research and decision-
making. In the future, certification by e.g. European Committee for Treatment and 
Research in Multiple Sclerosis (ECTRIMS) or European Society of Neuroradiology 
(ESNR) of centres and radiologists / neuroradiologists that fulfil the minimum 
technical requirements, have adequate quality control programmes and use 
standardised protocols may help to accelerate harmonisation.  
One of the most important prerequisites for the successful implementation of routine 
MRI evaluations (e.g. including atrophy quantification) into clinical practice is that 
payers (patients, drug companies, private insurance) and health authorities recognise 
its clinical value. To achieve this, the identification of the most robust MRI 
biomarkers for disease evolution and treatment response in the individual patient, 
definitions and thresholds for MRI activity, and their integration into patient risk 
stratification algorithms are crucial. Today, most existing data regarding markers of 
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treatment response are based on studies with IFNβ and may not apply to other DMDs 
that have different modes of action.5,78-80 Therefore, more research is warranted. As 
some DMDs may take up to 6 months to become effective (e.g. GA), an additional 
baseline scan at 3-6 months after initiation of treatment is recommended to adequately 
analyse changes over time and to minimise the pseudoatrophy effect.  
The current limitations of existing MRI techniques for use in clinical practice and the 
need for standardised protocols were confirmed by the polling results at the first Pan-
European MS Multi-stakeholder Colloquium. Indeed, when attendants were asked to 
rank priorities in MRI research, stimulating standardisation of imaging reports and 
development of software was considered highest priority, followed by improvement of 
image acquisition and analysis techniques for patient follow-up (Figure 3(a)). The 
opinion of clinicians about these issues were further explored in an online 
questionnaire about the optimisation of imaging / MRI for use in clinical practice 
undertaken in preparation for the second MS Multi-stakeholder Colloquium. Among 
the 143 respondents of this questionnaire, mostly neuroradiologists (70%), 77.8% 
indicated that they already used a standardised MRI protocol for MS patients in their 
practice. The majority (74.1%) indicated that incorporation of measures of brain 
volume loss in clinical practice would be valuable. Over 80% partly or fully agreed 
that the development of simplified but robust techniques should be accelerated in order 
to allow radiologists on site to perform measurements of brain volume loss themselves 
and to report directly to the neurologist. In addition, 57.3% of the respondents 
indicated that reimbursement of MRI analysis in MS should in the first place be 
obtained from insurance companies and public health organisations. 
 
Mult Scler  SUPPLEMENT MS Multi-stakeholder Colloquia: The Clinical Perspective 
final, 11/01/2016  22 
How to integrate the patient’s treatment expectations into individualised 
decision-making? 
In order to take a patient-tailored treatment decision, it is not only important to predict 
the patient’s treatment response and his/her risk of developing SAEs, but also to 
consider the patient’s treatment expectations. Physicians’ concerns and their 
willingness to accept SAEs in return for improved drug efficacy may differ 
substantially from patients’ preferences.111 In general, physicians may be more 
concerned about the physical manifestations of MS, while patients may be more 
worried about less tangible domains such as mental health, role limitations due to 
emotional problems and vitality. However, delaying disability progression remains the 
most important treatment expectation for patients, being more important than 
preventing SAEs and decreasing relapse rate (Figure 5).112,113 Hence, it is not 
surprising that patients might be more willing to accept SAEs in return for a reduced 
risk of disability progression than physicians.114 Given these differences in treatment 
perspectives between patients and physicians, neurologists should strongly encourage 
their patients to formulate their own values and preferences regarding their medical 
care.115 In addition, healthcare providers have a duty to ensure patients understand the 
complex information given to them. Patient preferences should be carefully 
considered, together with the available evidence on efficacy and tolerability for each 
treatment option, the patient’s predicted chance of treatment response and his/her 
predicted risk of SAEs. In this way, we can progress to personalised or patient-tailored 
decision making, choosing the treatment option that best matches the patient’s 
treatment expectations, with a good balance between desired efficacy, tolerability and 
quality of life improvement. 
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The importance of tailoring treatment for MS to each individual patient also became 
clear from the survey among the attendants of the first Pan-European MS Multi-
stakeholder Colloquium. When participants were asked to rank key issues regarding 
personalised treatment, evaluating the appropriateness of treatment at individual 
patient level turned out to be the key priority (Figure 3(b)). In contrast, further 
exploring and validating patient preferences was not frequently ranked among the top 
three priorities. This finding suggest that across stakeholders’ awareness integrating of 
individual patient’s treatment expectations into decision making in MS still needs to 
be improved.  
 
Conclusions 
Biomarkers may be very useful tools for individualised decision making in MS. They 
may assist in diagnosing MS, predicting and monitoring disability progression, and in 
predicting a patient’s treatment response and risk of SAEs. In current clinical practice, 
MRI markers are still the most important biomarkers for diagnosis and routine follow-
up of patients with MS, while they may also help to predict response to IFNβ or GA. 
In addition to clinical and MRI markers, several molecular biomarkers have been 
identified as well, with the level of NFs in CSF being among the most promising ones, 
both to predict disease progression and to monitor treatment response. 
 
Although biomarkers can theoretically be used to individualise treatment of patients 
with MS, their implementation in the clinical decision model currently remains very 
limited. The validation of biomarkers is a long (it can take 5-15 years before a 
potential biomarker has been validated for use in clinical practice) and complicated 
process, requiring replicated evidence of correlation with clinical measures and 
Mult Scler  SUPPLEMENT MS Multi-stakeholder Colloquia: The Clinical Perspective 
final, 11/01/2016  24 
evaluation of effectiveness, cost effectiveness, and predictive accuracy in clinical trials 
and real-life clinical practice.116 In addition, implementation of biomarkers into the 
decision model requires regulatory approval, reimbursement agreements, ability to 
interpret and use the results to take decisions, acceptance in clinical guidelines and 
patient and clinician acceptance. The implementation of a standardised MRI protocol 
for monitoring disease evolution would be an important first step towards a better 
evaluation of MS patients in the near future. Such efforts should be accompanied by 
dedicated training courses on this subject to maintaining a high level of competence. 
In addition, further development and evaluation of automated measurements that could 
easily be integrated into the clinical work flow should be fostered to improve 
practicability of such measurements and facilitate serial analysis and comparison 
across centres. In addition, more research is needed to discover new clinical, imaging, 
genetic and immunological biomarkers, to validate new and existing biomarkers and to 
implement them in clinical practice. Finally, patients’ preferences should be actively 
integrated into the decision-making process. In order to come to a patient-tailored 
treatment decision, the patient’s predicted risks of disability progression, treatment 
response and SAEs with a particular treatment should be carefully considered together 
with his/her treatment expectations. This will ultimately help neurologists optimise to 
drug choices to the each individual patient at the right moment during their disease 
course 
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Tables 
Table 1. Standardised brain MRI acquisition protocol for an optimised follow-up 
of MS patients developed by MAGNIMS .109  
Baseline evaluation 
 Mandatory sequences  
o Axial proton density or T2-FLAIR/T2-weighted  
o Sagittal 2D or 3D T2-FLAIR  
o 2D or 3D contrast-enhanced T1-weighted  
 Optional sequences  
o Unenhanced high-resolution isotropic 3D T1-weighted  
o 2D and/or 3D dual inversion recovery (DIR) 
o Axial diffusion-weighted imaging 
Follow-up examinations 
 Mandatory sequences  
o Axial proton density or T2-FLAIR/T2-weighted  
 Highly recommended sequence 
o 2D or 3D contrast-enhanced T1-weighted  
 Optional sequences  
o Unenhanced high-resolution isotropic 3D T1-weighted  
o 2D and/or 3D dual inversion recovery 
o Axial diffusion-weighted imaging 
FLAIR, fluid attenuated inversion recovery; MS, multiple sclerosis 
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Figure legends 
Figure 1. Schematic overview of risk factors and clinical and MRI biomarkers of 
progression in MS 
(GdE: gadolinium-enhancing; GM: grey matter; MR: magnetic resonance; 
MTI: magnetic transfer imaging) 
 
Figure 2.  Median time from disease onset to reach an Expanded Disability Status 
Scale (EDSS) score of 6, 8 and 10 for (a) the number of relapses (1, 2, or 
≥ 3) during year 1-2 after disease onset and (b) for the total number of 
relapses (1-2, 3-4 or  5) during the relapsing-remitting phase of 806 
patients followed for 28,000 patient-years in the Canadian London 
Ontario cohort 10 
 
Figure 3.  Polling results from the first Multi-stakeholder MS Colloquium 
showing priorities in (a) MRI research and implementation in clinical 
practice and (b) individualised treatment of MS. The x-axis shows 
percentages of points for each option (3 points for the first priority, 2 
points for the second priority and 1 point for the third priority) versus 
the total number of points of all options together 
 (AEs: adverse events; DMDs: disease-modifying drugs; MOAs: mechanisms 
of action; OCT: optical coherence tomography; Tx: treatment) 
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Figure 4.  Treatment algorithm depicting the difference between escalation and 
induction therapy 
(BG12: dimethyl fumarate; GA: glatiramer acetate; idx: JCV antibody index; 
IFN: interferon; JCV: John Cunningham virus; NTZ: natalizumab; tiw: 3 times 
weekly) 
 
Figure 5. Delaying disability progression is the most important treatment attribute 
for patients with multiple sclerosis (MS). 651 patients with MS (mean 
age: 47 years) with a broad range of  disability levels were asked to 
choose between hypothetical pairs of treatment alternatives with 
varying levels of clinical efficacy and associated risks. From these 
trade-off tasks, the relative importance of each attribute was 
determined. Reproduced from Johnson et al, 200985, with kind 
permission from Springer Science and Business Media. 
 
